Business Context and Reporting Period
Company: iSpecimen Inc. (ISPC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: iSpecimen operates a proprietary online marketplace connecting medical researchers with hospitals and laboratories to procure human biospecimens (biofluids, tissues, cells). The company operates as a single reporting segment focused on biospecimen procurement.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $156,009 | $1,057,510 |
| Net Loss | $(2,275,221) | $(1,658,396) |
| Loss Per Share (Basic/Diluted) | $(6.66) | $(28.55) |
| Cash and Cash Equivalents | $2,818,989 | $782,563 |
| Working Capital | $(2,115,634) | $(6,231,306 - $6,954,590 = Negative) |
| Total Assets | $6,609,658 | $9,531,410 |
| Total Liabilities | $5,795,620 | $6,443,179 |
| Accumulated Deficit | $(84,625,370) | $(73,521,013) |
Note: Working capital is negative (Current Liabilities exceed Current Assets). The filing explicitly states a negative working capital of $2,115,634 as of March 31, 2026.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 85% ($901,501) compared to Q1 2025. This was driven by a 61% drop in specimen count (from 2,309 to 890) and a 62% decrease in average selling price per specimen.
- Expense Reductions:
- Cost of Revenue: Decreased 87% due to lower specimen volume and lower average cost per specimen.
- Technology Expenses: Decreased 55% primarily due to reduced amortization and payroll, despite $700,000 in new software capitalization.
- Fulfillment & Supply Development: Both decreased by 64% due to workforce reductions.
- Sales & Marketing Spike: Expenses increased 344% ($1.195 million) due to a $1.5 million increase in external marketing expenses, partially offset by payroll reductions.
- Other Income: Net other income increased significantly to $263,182 (from a loss of $20,001) due to a $264,144 gain on debt settlement and reduced sales tax penalties.
- Cash Flow: Net cash used in operating activities increased to $3.36 million (from $1.10 million) due to higher net loss and changes in working capital (specifically a $507k increase in prepaid expenses).
Outlook, Risks, and Contingencies
Going Concern Uncertainty
The filing raises substantial doubt regarding the company's ability to continue as a going concern for one year from the filing date. This is due to recurring losses, an accumulated deficit of $84.6 million, and negative working capital. Management's plan to mitigate this includes generating additional revenue, deferring projects, and reducing operating expenses, though success is not assured.
Legal Proceedings
- Focus Technology Solutions: Ongoing dispute regarding non-payment for IT services. A settlement agreement was breached by the vendor. The company is required to deposit 15% of net monthly revenue into escrow (up to $420,000) as pre-judgment security, though a court clarification allows for no deposit if net revenue is negative.
- Azenta US, Inc. Claim for $651,262 for breach of contract. Company has offered $125,000 to settle; no response received.
- Krisbio, LLC: Claim for $266,380 for breach of contract. Discovery has not begun.
- EGS (Ellenoff Grossman & Schole): Settled for $200,000 in Q1 2026.
Sales Tax Liability
The company identified a material weakness in internal controls regarding sales tax collection. As of March 31, 2026, the estimated sales tax liability is approximately $235,000 plus $55,000 in interest and penalties. The company is actively collecting back taxes from non-exempt customers.
Subsequent Events
- Reverse Stock Split: A 1-for-40 reverse stock split became effective on April 27, 2026.
- Capital Raise: On May 8, 2026, the company entered an agreement to sell 488,281 shares at $5.12 per share (offering closed May 11, 2026).
Investor Verification Checklist
- Liquidity Runway: Verify if the May 2026 capital raise proceeds are sufficient to cover the $2.1 million working capital deficit and ongoing burn rate given the "substantial doubt" disclosure.
- Revenue Concentration: Confirm the status of "Customer A," who accounted for 54.42% of Q1 2026 revenue and 68.49% of accounts receivable.
- Supplier Concentration: Assess risk regarding "Supplier A," who provided 59.75% of total purchases in Q1 2026.
- Legal Exposure: Monitor the outcome of the Focus Technology Solutions litigation and the potential requirement to fund the $420,000 escrow account if net revenue turns positive.
- Internal Controls: Review progress on remediation of the material weakness related to sales tax collection and customer exemption documentation.
- Stock Split Impact: Verify the trading status and liquidity of the stock following the 1-for-40 reverse split effective April 27, 2026.